TheProductLawyers.com reports on the status of the current Multidistrict Litigation (MDL 2592) that consolidated the more than 2,800 Xarelto lawsuits filed against the subsidiary company of the Johnson and Johnson Corporation, Janssen Pharmaceuticals, and Bayer AG. The MDL is being overseen by the Honorable Judge Eldon E. Fallon in the Eastern District of Louisiana.
The plaintiffs involved in all the cases in the MDL are making similar allegations against the drug's manufacturers that the blood thinner Xarelto can induce very sudden and spontaneous internal and external uncontrollable bleeding that has resulted in many fatalities as well. Judge Fallon has set a target date of spring 2017 to commence the first 4 bellwether trials against the defendants to be selected out of a pool of 40 cases. As the MDL inches toward the beginning of the litigation process, 400 more cases were added to it just in the month of August 2015 alone.
The cases that are the focus of the MDL are not the only ones that are progressing forward as a group litigation. The Court of Common Pleas in Philadelphia, PA has created a mass tort program comprised of 550 cases with all of them naming Janssen and Bayer as defendants, claiming similar allegations related to uncontrollable bleeding.
Xarelto plaintiffs are somewhat encouraged in their efforts based on actions taken with Pradaxa, another new-generation blood thinner that experienced the same kind of public scrutiny that Xarelto is now receiving. Pradaxa was released on the market by Boehringer Ingelheim in 2010, and it quickly became the focus of more than 4,000 lawsuits because of thousands of adverse event reports that were filed, 750 of which were reporting fatalities. Xarelto plaintiffs are hopeful that what happened with Pradaxa will occur in their situation. On the eve of the start of the trial Pradaxa's manufacturer agreed to a $650 million settlement in lieu of going to trial.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-478-9711.
TheProductLawyers.com is a resource website sponsored by Banville Law to provide information on pending lawsuits against defective products, drugs and medical devices.
165 West End Ave #1h,
New York, NY 10023
November 30, 2016 – Research Indicates New Form Of Treating Ovarian Cancer As Talcum Powder Lawsuit Numbers Climb
November 30, 2016 – Parties in Talcum Powder Lawsuit In Missouri Exchange Briefings
November 30, 2016 – J&J Requests Disclosure Of Third Party Litigation Financing In Talcum Powder Lawsuit
November 30, 2016 – Delaware Sees 10 New Talcum Powder Lawsuit Filings
November 29, 2016 – Philadelphia Talcum Powder Lawsuit Filed Against Johnson & Johnson To Proceed
November 29, 2016 – Pennsboro Woman Files Talcum Powder Lawsuit On Behalf Of Her Deceased Mother
November 29, 2016 – Bioimaging Helps Early Detection Of Ovarian Cancer As Talcum Powder Lawsuit Filings Continue
November 28, 2016 – FDA Follow-Up: How Officials Have Responded To The Influx Of Talcum Powder Lawsuit Filings
November 28, 2016 – Talc Uses: A Look At The Product At The Center Of Talcum Powder Lawsuit Filings
November 28, 2016 – More Women Encouraged To File A Talcum Powder Lawsuit After Verdicts